Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
In development
Reference number: GID-TA10905
Expected publication date: TBC
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies have been revised. It is anticipated that the appraisal will begin in late-October 2023 when we will write to you about how you can get involved.